OTCMKTS:VDRM ViaDerma (VDRM) Stock Price, News & Analysis $0.0007 +0.00 (+600.00%) As of 08/8/2025 01:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About ViaDerma Stock (OTCMKTS:VDRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ViaDerma alerts:Sign Up Key Stats Today's Range$0.0007▼$0.000750-Day Range N/A52-Week Range$0.00▼$0.02Volume10,000 shsAverage Volume1.40 million shsMarket CapitalizationN/AP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California. Read More Receive VDRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViaDerma and its competitors with MarketBeat's FREE daily newsletter. Email Address VDRM Stock News HeadlinesViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market ChangesJuly 16, 2025 | finance.yahoo.comViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory ComplianceJune 4, 2025 | globenewswire.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in IndiaJanuary 21, 2025 | finance.yahoo.comViaDerma Announces Significant 2024 Achievements and International ExpansionDecember 10, 2024 | markets.businessinsider.comViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow GrowthOctober 3, 2024 | finance.yahoo.comViaDerma Completes First Shipment of 500,000 Units to NigeriaSeptember 10, 2024 | stockhouse.comViaDerma Announces Shipment of 500,000 Units of its Flagship Product to NigeriaAugust 14, 2024 | finance.yahoo.comSee More Headlines VDRM Stock Analysis - Frequently Asked Questions How have VDRM shares performed this year? ViaDerma's stock was trading at $0.0074 on January 1st, 2025. Since then, VDRM shares have decreased by 90.5% and is now trading at $0.0007. How do I buy shares of ViaDerma? Shares of VDRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ViaDerma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ViaDerma investors own include Tesla (TSLA), Dominari (DOMH), Co-Diagnostics (CODX), CEA Industries (CEAD), Organicell Regenerative Medicine (BPSR), AutoZone (AZO). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:VDRM CIKN/A Webviadermalicensing.com Phone(310) 734-6111FaxN/AEmployees75Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:VDRM) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViaDerma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ViaDerma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.